Aethlon Medical, Inc. — Form 10-Q Summary
Business context and reporting period. This filing covers the quarter and six months ended September 30, 2020, the company’s fiscal second quarter. Aethlon is a clinical-stage medical technology company developing the Hemopurifier for cancer and life-threatening viral infections, and owns a majority interest in diagnostic subsidiary Exosome Sciences, Inc. The filing is unaudited.
Financial performance and position
| Metric | Three months ended September 30, 2020 | Six months ended September 30, 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1.771 million | $3.182 million |
| Operating loss | $1.771 million | $3.182 million |
| Net loss | $1.771 million | $3.183 million |
| Basic and diluted loss per share | $0.15 | $0.29 |
- Year-over-year: Quarterly operating expenses increased 4.1%, while six-month operating expenses declined 3.5%. Six-month net loss improved from $3.774 million in 2019, partly because the prior period included a $447,011 debt-extinguishment loss and higher interest expense. Six-month revenue fell from $30,000 to zero.
- Cash and liquidity: Cash was $14.473 million at September 30, up from $9.605 million at March 31, 2020. Working capital was $13.262 million, versus $8.973 million. Management said cash on hand was expected to fund operations for at least 12 months from issuance of the statements.
- Cash flows: Six-month operating cash use was $2.329 million, investing cash use was $23,000, and financing provided $7.220 million. The resulting cash increase was $4.868 million.
- Debt and liabilities: The company reported no convertible notes outstanding; those notes were paid in July 2019. Total liabilities were $1.490 million, including $92,603 of current lease liability. There were no off-balance-sheet arrangements.
- Margins: Not meaningful to assess because the company reported no revenue in the 2020 quarter or six-month period.
Material changes and financing
- The company raised $7.261 million net through its at-the-market stock program, selling 2,685,600 shares at an average net price of $2.70 per share. Shares outstanding rose from 9,366,873 at March 31 to 12,088,313 at September 30, a substantial increase in share count.
- General and administrative expense increased, principally from Hemopurifier inventory-building supplies and clinical-trial costs. For six months, this increase was partly offset by lower payroll-related expense—largely reduced stock compensation—and lower professional fees.
- The company invoiced the NIH/NCI $407,022 during the six months but recognized none as revenue because related milestones had not been achieved; the amount was recorded as deferred revenue. Deferred revenue was $507,022 at September 30.
Outlook, clinical progress, and risks
- The Hemopurifier has FDA Breakthrough Device designation for specified cancer and viral-disease indications. The head-and-neck cancer early feasibility study, planned for 10–12 patients with pembrolizumab, was open for enrollment at UPMC Hillman Cancer Center.
- The FDA approved a COVID-19 feasibility-study supplement in June 2020. The planned study may enroll up to 40 ICU patients at up to 20 U.S. centers; initial sites had IRB approval and were preparing to enroll. The company also reported one patient treated under emergency-use provisions who completed eight daily treatments; this single case does not establish efficacy.
- Management said it expected continued losses and negative operating cash flows for the foreseeable future and planned significant spending on raw materials and contract manufacturing, subject to raising additional capital. No specific revenue, earnings, or clinical-trial timeline guidance was provided.
- COVID-19 could affect trial timing, costs, shipping, operations, and access to capital; management said the future impact was uncertain. Other disclosed risks include regulatory approval, patent protection, commercialization, competition, product liability, and maintaining Nasdaq listing compliance.
- The company reported no pending or threatened legal proceedings and no material changes to contractual commitments outside the ordinary course. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Track whether the NIH/NCI contract and grant milestones are met and deferred revenue is ultimately recognized.
- Verify clinical-trial enrollment, timing, safety results, and whether any reported treatment outcomes are supported by broader clinical evidence.
- Assess cash runway against continuing operating cash use and planned manufacturing and clinical spending; verify the assumptions underlying management’s 12-month estimate.
- Review remaining ATM capacity, subsequent share issuance, and potential dilution from outstanding warrants, options, and restricted stock units.
- Monitor COVID-19-related trial and supply-chain effects, regulatory progress, and Nasdaq listing compliance.